| SAN MATEO, Calif., Nov. 14, 2011 /PRNewswire/ -- Nile Therapeutics, Inc. (OTCQB: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced its third quarter financial results for 2011. Financial Results For third quarter of 2011, Nile reported research and development collaboration income relating to its cenderitide program of approximately $0.8 million, as compared to none in the third quarter of 2010. The net loss for the third quarter of 201...continued NLTX Healthcare Drugs |
Monday, November 14, 2011
Nile Therapeutics Reports 2011 Third Quarter Financial Results
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment